secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caris Life Sciences, Inc. (CAI)
CIK:        0002019410
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0002019410-26-000011
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caris Q4 net income $82M; FY25 rev $812M (+97%); guides FY26 rev $1.0-1.02B
---------------------------------------------------------------------------

- Q4 2025 revenue $292.9M (+125% YoY); net income $82.0M vs loss of $36.9M prior year.
- Full year 2025 revenue $812.0M (+97% YoY); net loss narrowed to $68.1M from $281.9M; Adj. EBITDA $137.7M.
- Gross margin improved to 75% in Q4 (from 54%) and 66% for FY (from 43%).
- FY26 revenue guidance $1.0-1.02B (23-26% growth); molecular profiling rev growth ~21-22%.
- Interim readout of Achieve 1 study for Caris Detect MCED test completed; launch expected H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2019410/000201941026000011/0002019410-26-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2019410/000201941026000011/cai-20260226.htm
  HTML page:      https://secwatch.observer/filing/0002019410-26-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer